FAM111A

Across TCGA pan-cancer cohorts, FAM111A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM111A data layer compared with 20 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM111A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM111A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where FAM111A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.846	.004	12	view →
LUAD	DFS	Quartile	III,IV	0.916	0.400	.006	9	view →
PDAC	OS	Quartile	All	0.665	1.000	.004	6	view →
HNSC	DFS	Quartile	III,IV	0.871	0.353	.024	5	view →
UCEC	DFS	Quartile	All	0.764	0.969	.023	4	view →
GBM	OS	Median	All	0.629	0.406	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM111A–CCRCC (DFS)

Open the CCRCC breakdown →